pREVention and management tools for rEducing antibiotic Resistance in high prevalence SEttings (REVERSE) project

Description of impact

The pREVention and management tools for rEducing antibiotic Resistance in high prevalence SEttings (REVERSE) project aims to tackle the spread of antimicrobial resistance (AMR) in hospitals through the implementation and evaluation of infection prevention and control (IPC) and antibiotic stewardship (ABS) intervention bundles.UKHSA is a partner within the REVERSE consortium, a European Commission Horizon 2020 funded consortium conducting a prospective multi-national clinical trial of
preventive AMR interventions across 24 hospitals in 4 European countries. UKHSA leads the Cost-effectiveness Work Package, in collaboration with the University of Oxford and ISGlobal, Barcelona, using quantitative and qualitative approaches to assess the cost-effectiveness and affordability of these interventions, as well as the potential barriers and facilitators for implementation in low- and middle-income countries
(LMICs). This has involved a systematic review of evidence on the cost-effectiveness of hospital-based interventions for healthcare-associated infection (HCAI) and AMR, published in April 2025, and ongoing work to develop a dynamic, health-economic model to assess the cost-effectiveness of the interventions. UKHSA is also leveraging this work to conduct a model-based evaluation of the cost effectiveness of admission screening strategies for carbapenemase-producing Enterobacterales (CPE), a multidrug-resistant bacteria, in English hospitals.
The work aims to inform national guidelines and clinical practice in hospitals
internationally by supporting the adoption of clinically and economically effective interventions to address the spread of multidrug-resistant organisms. It is also aiming to contribute to research methods by attempting to incorporate the impact of the interventions on levels of AMR in the wider population

Impact date	28 Aug 2025
Category of impact	Health impacts